Digital Jagran

Information, Information and Information

Biotech

Avalyn targets $182 million IPO to advance inhaled respiratory therapies

Avalyn Pharma plans a $182 million IPO to fund late-stage trials of inhaled therapies for lung diseases, including treatments for pulmonary fibrosis.

Surya Pratap Singh

4/27/2026, 5:56:15 AM

0 min read

Avalyn targets $182 million IPO to advance inhaled respirato... | Digital Jagran | Digital Jagran